RecruitingPhase 2NCT06163573

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-based Engineered Cartilage Implantation in a Randomized, Controlled, Multi-center Phase II Clinical Trial

Sponsor

University Hospital, Basel, Switzerland

Enrollment

75 participants

Start Date

Jun 6, 2024

Study Type

INTERVENTIONAL

Conditions

Patellofemoral osteoarthritis

Summary

The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections. The engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called N-TEC and a biological treatment called Platelet rich plasma for people with patellofemoral osteoarthritis. The study is currently recruiting participants at 9 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALN-TEC

Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.

BIOLOGICALPlatelet rich plasma

Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks. Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks.